{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T13:47:19Z","timestamp":1775483239527,"version":"3.50.1"},"reference-count":117,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["POCI-01-0145-FEDER-029584"],"award-info":[{"award-number":["POCI-01-0145-FEDER-029584"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>ADB-FUBINACA and AMB-FUBINACA are two synthetic indazole-derived cannabinoid receptor agonists, up to 140- and 85-fold more potent, respectively, than trans-\u22069-tetrahydrocannabinol (\u22069-THC), the main psychoactive compound of cannabis. Synthesised in 2009 as a pharmaceutical drug candidate, the recreational use of ADB-FUBINACA was first reported in 2013 in Japan, with fatal cases being described in 2015. ADB-FUBINACA is one of the most apprehended and consumed synthetic cannabinoid (SC), following AMB-FUBINACA, which emerged in 2014 as a drug of abuse and has since been responsible for several intoxication and death outbreaks. Here, we critically review the physicochemical properties, detection methods, prevalence, biological effects, pharmacodynamics and pharmacokinetics of both drugs. When smoked, these SCs produce almost immediate effects (about 10 to 15 s after use) that last up to 60 min. They are rapidly and extensively metabolised, being the O-demethylated metabolite of AMB-FUBINACA, 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamide)-3-methylbutanoic acid, the main excreted in urine, while for ADB-FUBINACA the main biomarkers are the hydroxdimethylpropyl ADB-FUBINACA, hydroxydehydrodimethylpropyl ADB-FUBINACA and hydroxylindazole ADB-FUBINACA. ADB-FUBINACA and AMB-FUBINACA display full agonism of the CB1 receptor, this being responsible for their cardiovascular and neurological effects (e.g., altered perception, agitation, anxiety, paranoia, hallucinations, loss of consciousness and memory, chest pain, hypertension, tachycardia, seizures). This review highlights the urgent requirement for additional studies on the toxicokinetic properties of AMB-FUBINACA and ADB-FUBINACA, as this is imperative to improve the methods for detecting and quantifying these drugs and to determine the best exposure markers in the various biological matrices. Furthermore, it stresses the need for clinicians and pathologists involved in the management of these intoxications to describe their findings in the scientific literature, thus assisting in the risk assessment and treatment of the harmful effects of these drugs in future medical and forensic investigations.<\/jats:p>","DOI":"10.3390\/ph14030186","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T02:08:17Z","timestamp":1614305297000},"page":"186","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Overview of Synthetic Cannabinoids ADB-FUBINACA and AMB-FUBINACA: Clinical, Analytical, and Forensic Implications"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8844-2003","authenticated-orcid":false,"given":"Carolina","family":"Lobato-Freitas","sequence":"first","affiliation":[{"name":"UCIBIO-REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7327-1598","authenticated-orcid":false,"given":"Andreia Machado","family":"Brito-da-Costa","sequence":"additional","affiliation":[{"name":"IINFACTS-Institute of Research and Advanced Training in Health Sciences and Technologies, Department of Sciences, University Institute of Health Sciences (IUCS), CESPU, CRL, 4585-116 Gandra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7430-6297","authenticated-orcid":false,"given":"Ricardo Jorge","family":"Dinis-Oliveira","sequence":"additional","affiliation":[{"name":"UCIBIO-REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"},{"name":"IINFACTS-Institute of Research and Advanced Training in Health Sciences and Technologies, Department of Sciences, University Institute of Health Sciences (IUCS), CESPU, CRL, 4585-116 Gandra, Portugal"},{"name":"Department of Public Health and Forensic Sciences, and Medical Education, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6650-5285","authenticated-orcid":false,"given":"Helena","family":"Carmo","sequence":"additional","affiliation":[{"name":"UCIBIO-REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3858-3494","authenticated-orcid":false,"given":"F\u00e9lix","family":"Carvalho","sequence":"additional","affiliation":[{"name":"UCIBIO-REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5656-0897","authenticated-orcid":false,"given":"Jo\u00e3o Pedro","family":"Silva","sequence":"additional","affiliation":[{"name":"UCIBIO-REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7331-9157","authenticated-orcid":false,"given":"Diana","family":"Dias-da-Silva","sequence":"additional","affiliation":[{"name":"UCIBIO-REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"},{"name":"IINFACTS-Institute of Research and Advanced Training in Health Sciences and Technologies, Department of Sciences, University Institute of Health Sciences (IUCS), CESPU, CRL, 4585-116 Gandra, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,25]]},"reference":[{"key":"ref_1","unstructured":"EMCDDA (2020). European Drug Report 2020: Trends and Developments, European Union Publications Office. Available online: https:\/\/www.emcdda.europa.eu\/system\/files\/publications\/13236\/TDAT20001ENN_web.pdf."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1080\/15563650.2019.1580371","article-title":"Fatal Intoxication with New Synthetic Cannabinoids AMB-FUBINACA and EMB-FUBINACA","volume":"57","author":"Adamowicz","year":"2019","journal-title":"Clin. Toxicol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa1610300","article-title":"\u201cZombie\u201d Outbreak caused by the Synthetic Cannabinoid AMB-FUBINACA in New York","volume":"376","author":"Adams","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1080\/15563650.2017.1307385","article-title":"Supraventricular Tachycardia and Acute Confusion Following Ingestion of E-cigarette Fluid Containing AB-FUBINACA and ADB-FUBINACA: A Case Report with Quantitative Analysis of Serum Drug Concentrations","volume":"55","author":"Lam","year":"2017","journal-title":"Clin. Toxicol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Shanks, K.G., Clark, W., and Behonick, G. (2016). Death Associated with the Use of the Synthetic Cannabinoid ADB-FUBINACA. J. Anal. Toxicol., 236\u2013239.","DOI":"10.1093\/jat\/bkv142"},{"key":"ref_6","unstructured":"EMCDDA (2018). European Drug Report 2018: Trends and Developments, European Union Publications Office. Available online: https:\/\/www.emcdda.europa.eu\/system\/files\/publications\/8585\/20181816_TDAT18001ENN_PDF.pdf."},{"key":"ref_7","unstructured":"EMCDDA (2018). Fentanils and Synthetic Cannabinoids: Driving Greater Complexity into the Drug Situation, Publications Office of the European Union. Available online: http:\/\/www.emcdda.europa.eu\/system\/files\/publications\/8870\/2018-2489-td0118414enn.pdf."},{"key":"ref_8","unstructured":"Buchler, I.P., Hayes, M.J., Hegde, S.G., Hockerman, S.L., Jones, D.E., and Kortum, S.W. (2009). Indazole Derivatives. (2009\/106980-A2), Patent WO."},{"key":"ref_9","first-page":"223","article-title":"Two New-type Cannabimimetic Quinolinyl Carboxylates, QUPIC and QUCHIC, two New Cannabimimetic Carboxamide Derivatives, ADB-FUBINACA and ADBICA, and five Fynthetic Cannabinoids Detected with a Thiophene Derivative \u03b1-PVT and an Opioid Receptor Agonist AH-7921 Identified in Illegal Products","volume":"31","author":"Uchiyama","year":"2013","journal-title":"Forensic Sci. Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"682","DOI":"10.2174\/1570159X15666161108123419","article-title":"In Vitro Metabolite Profiling of ADB-FUBINACA, a New Synthetic Cannabinoid","volume":"15","author":"Carlier","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1021\/acschemneuro.6b00137","article-title":"Pharmacology of Valinate and Tert-leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and their Analogues","volume":"7","author":"Banister","year":"2016","journal-title":"ACS Chem. Neurosci."},{"key":"ref_12","unstructured":"Ministry of Health (2020, March 16). AB-FUBINACA and AMB FUBINACA: Report to the Expert Advisory Committee on Drugs, Available online: https:\/\/www.health.govt.nz\/our-work\/regulation-health-and-disability-system\/psychoactive-substances-regulation\/synthetic-cannabis."},{"key":"ref_13","unstructured":"DEA (2020, May 21). Annual Emerging Threat Report, Available online: https:\/\/publicintelligence.net\/dea-emerging-threats-reports-2017\/."},{"key":"ref_14","unstructured":"World Drug Report (2020, March 24). SIRIUS\u2014United Nations Publication. Available online: https:\/\/www.unodc.org\/wdr2018."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.JAA.0000525914.28344.e2","article-title":"Synthetic Cannabinoids: A Review of the Clinical Implications of a New Drug of Choice","volume":"30","author":"Freund","year":"2017","journal-title":"JAAPA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/7854_2016_60","article-title":"Pharmacological and Toxicological Effects of Synthetic Cannabinoids and their Metabolites","volume":"32","author":"Tai","year":"2016","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1124\/jpet.117.246983","article-title":"Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB-and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA","volume":"365","author":"Gamage","year":"2018","journal-title":"J. Pharm. Exp."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.drugalcdep.2014.08.005","article-title":"Synthetic Cannabinoids: Epidemiology, Pharmacodynamics, and Clinical Implications","volume":"144","author":"Castaneto","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/dta.2517","article-title":"Application of an Activity-based Receptor Bioassay to Investigate the In Vitro Activity of Selected Indole-and Indazole-3-carboxamide-based Synthetic Cannabinoids at CB1 and CB2 Receptors","volume":"11","author":"Noble","year":"2019","journal-title":"Drug Test. Anal."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1021\/acschemneuro.5b00112","article-title":"Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA","volume":"6","author":"Banister","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Zattera, L., Errasti, J., and Superv\u00eda, A. (2018). Intoxication by the Synthetic Cannabinoid 5-fluoro-ABD, Acquired as Ketamine. Med. Clin.","DOI":"10.1016\/j.medcle.2018.01.031"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jemermed.2014.12.038","article-title":"A Common Source Outbreak of Severe Delirium Associated with Exposure to the Novel Synthetic Cannabinoid ADB-PINACA","volume":"48","author":"Schwartz","year":"2015","journal-title":"J. Emerg. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1056\/NEJMp1505328","article-title":"Synthetic Cannabinoid-related Illnesses and Deaths","volume":"373","author":"Trecki","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/15563650.2015.1110590","article-title":"A Systematic Review of Adverse Events Arising from the Use of Synthetic Cannabinoids and their Associated Treatment","volume":"54","author":"Tait","year":"2016","journal-title":"Clin. Toxicol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4103\/1947-2714.185038","article-title":"Acute Rhabdomyolysis Following Synthetic Cannabinoid Ingestion","volume":"8","author":"Adedinsewo","year":"2016","journal-title":"N. Am. J. Med. Sci."},{"key":"ref_26","unstructured":"EMCDDA (2020, May 13). Perspectives on Drugs: Synthetic Cannabinoids in Europe. Available online: https:\/\/www.emcdda.europa.eu\/system\/files\/publications\/2753\/POD_Synthetic%20cannabinoids_0.pdf."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Tamama, K.L. (2019). Newly Emerging Drugs of Abuse. Handb. Exp. Pharm.","DOI":"10.1007\/164_2019_260"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.cell.2018.11.040","article-title":"Structure of a Signaling Cannabinoid Receptor 1-G Protein Complex","volume":"176","author":"Kumar","year":"2019","journal-title":"Cell"},{"key":"ref_29","unstructured":"WHO (2020, September 22). Critical Review Report: FUB-AMB (MMB-FUBINACA, AMB-FUBINACA). World Health Organ Tech Rep Ser, Available online: https:\/\/www.who.int\/medicines\/access\/controlled-substances\/Fub_amb.pdf."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.chroma.2016.10.049","article-title":"Enantioseparation of the carboxamide-type synthetic cannabinoids N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide and methyl [1-(5-fluoropentyl)-1H-indazole-3-carbonyl]-valinate in illicit herbal products","volume":"1473","author":"Doi","year":"2016","journal-title":"J. Chromatogr. A"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3389\/fchem.2019.00321","article-title":"Enantiospecific synthesis, chiral separation, and biological activity of four indazole-3-carboxamide-type synthetic cannabinoid receptor agonists and their detection in seized drug samples","volume":"7","author":"Antonides","year":"2019","journal-title":"Front. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11419-017-0378-5","article-title":"Evaluation of carboxamide-type synthetic cannabinoids as CB 1\/CB 2 receptor agonists: Difference between the enantiomers","volume":"36","author":"Doi","year":"2018","journal-title":"Forensic Toxicol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Antonides, L.H., Cannaert, A., Norman, C., NicD\u00e1eid, N., Sutcliffe, O.B., Stove, C.P., and McKenzie, C.J.D.T. (2020). Shape matters: The application of activity-based in vitro bioassays and chiral profiling to the pharmacological evaluation of synthetic cannabinoid receptor agonists in drug-infused papers seized in prisons. Drug Test. Anal.","DOI":"10.1002\/dta.2965"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1021\/acschemneuro.0c00591","article-title":"Exploring Stereochemical and Conformational Requirements at Cannabinoid Receptors for Synthetic Cannabinoids Related to SDB-006, 5F-SDB-006, CUMYL-PICA, and 5F-CUMYL-PICA","volume":"11","author":"Ametovski","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"ref_35","unstructured":"Chemicals, C. (2020, March 27). ADB-FUBINACA. Available online: www.caymanchem.com\/product\/142922018."},{"key":"ref_36","unstructured":"DEA (2020, March 27). ADB-FUBINACA, Available online: http:\/\/swgdrug.org\/Monographs\/ADB-FUBINACA.pdf."},{"key":"ref_37","unstructured":"WHO (2020, September 22). Critical Review Report: ADB-FUBINACA. World Health Organ Tech Rep Ser, Available online: https:\/\/www.who.int\/medicines\/access\/controlled-substances\/ADB_Fubinaca.pdf."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/bmc.3155","article-title":"UPLC\/ESI-MS\/MS-based Determination of Metabolism of Several New Illicit Drugs, ADB-FUBINACA, AB-FUBINACA, AB-PINACA, QUPIC, 5F-QUPIC and \u03b1-PVT, by Human Liver Microsome","volume":"28","author":"Takayama","year":"2014","journal-title":"Biomed. Chromatogr."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3389\/fchem.2019.00240","article-title":"Analysis of AMB-FUBINACA Biotransformation Pathways in Human Liver Microsome and Zebrafish Systems by Liquid Chromatography-High Resolution Mass Spectrometry","volume":"7","author":"Xu","year":"2019","journal-title":"Front. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11419-018-0430-0","article-title":"Toxic by Design? Formation of Thermal Degradants and Cyanide from Carboxamide-type Synthetic Cannabinoids CUMYL-PICA, 5F-CUMYL-PICA, AMB-FUBINACA, MDMB-FUBINACA, NNEI, and MN-18 During Exposure to High Temperatures","volume":"37","author":"Kevin","year":"2019","journal-title":"Forensic Toxicol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1002\/dta.2133","article-title":"Freeze-thaw Stability and Long-term Stability of 84 Synthetic Cannabinoids in Serum","volume":"9","author":"Hess","year":"2017","journal-title":"Drug Test. Anal."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/dta.2096","article-title":"Rapid and Sensitive Screening and Confirmation of Thirty-four Aminocarbonyl\/Carboxamide (NACA) and Arylindole Synthetic Cannabinoid Drugs in Human Whole Blood","volume":"9","author":"Tynon","year":"2017","journal-title":"Drug Test. Anal."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00216-014-8118-8","article-title":"Nontargeted SWATH Acquisition for Identifying 47 Synthetic Cannabinoid Metabolites in Human Urine by Liquid Chromatography-high-resolution Tandem Mass Spectrometry","volume":"407","author":"Scheidweiler","year":"2015","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.forsciint.2016.09.005","article-title":"Towards a Validation of Surface-enhanced Raman Scattering (SERS) for use in Forensic Science: Repeatability and Reproducibility Experiments","volume":"268","author":"Muehlethaler","year":"2016","journal-title":"Forensic Sci. Int."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/dta.2659","article-title":"Comprehensive Investigation on Synthetic Cannabinoids: Metabolic Behavior and Potency Testing, Using 5F-APP-PICA and AMB-FUBINACA as Model Compounds","volume":"11","author":"Noble","year":"2019","journal-title":"Drug Test. Anal."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3109\/03602532.2015.1137307","article-title":"Metabolomics of \u03949-tetrahydrocannabinol: Implications in Toxicity","volume":"48","year":"2016","journal-title":"Drug Metab. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1758-2946-6-22","article-title":"Using Cheminformatics to Predict Cross Reactivity of \u201cDesigner Drugs\u201d to their Currently Available Immunoassays","volume":"6","author":"Krasowski","year":"2014","journal-title":"J. Cheminform."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/dta.1702","article-title":"Performance Characteristics of an ELISA Screening Assay for Urinary Synthetic Cannabinoids","volume":"7","author":"Spinelli","year":"2015","journal-title":"Drug Test. Anal."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jemermed.2016.09.023","article-title":"Synthetic Cannabinoid Abuse Resulting in ST-segment Elevation Myocardial Infarction Requiring Percutaneous Coronary Intervention","volume":"52","author":"Hamilton","year":"2017","journal-title":"J. Emerg. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11419-017-0364-y","article-title":"In Vivo Metabolism of the New Synthetic Cannabinoid APINAC in Rats by GC\u2013MS and LC\u2013QTOF-MS","volume":"35","author":"Savchuk","year":"2017","journal-title":"Forensic Toxicol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.talanta.2016.11.002","article-title":"Surface Enhanced Raman Spectroscopy (SERS) as a Method for the Toxicological Analysis of Synthetic Cannabinoids","volume":"164","author":"Mostowtt","year":"2017","journal-title":"Talanta"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s11419-017-0356-y","article-title":"Detection of Metabolites of Two Synthetic Cannabimimetics, MDMB-FUBINACA and ADB-FUBINACA, in Authentic Human Urine Specimens by Accurate Mass LC\u2013MS: A Comparison of Intersecting Metabolic Patterns","volume":"35","author":"Kavanagh","year":"2017","journal-title":"Forensic Toxicol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s11419-015-0275-8","article-title":"Identification of AB-FUBINACA Metabolites in Human Hepatocytes and Urine Using High-resolution Mass Spectrometry","volume":"33","author":"Castaneto","year":"2015","journal-title":"Forensic Toxicol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1373\/clinchem.2016.267575","article-title":"Distinguishing Intake of New Synthetic Cannabinoids ADB-PINACA and 5F-ADB-PINACA with Human Hepatocyte Metabolites and High-resolution Mass Spectrometry","volume":"63","author":"Carlier","year":"2017","journal-title":"Clin. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.toxlet.2019.10.003","article-title":"Biodistribution and Metabolic Profile of 3, 4-dimethylmethcathinone (3, 4-DMMC) in Wistar Rats Through Gas Chromatography\u2013Mass Spectrometry (GC\u2013MS) Analysis","volume":"320","author":"Rouxinol","year":"2020","journal-title":"Toxicol. Lett."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11419-014-0245-6","article-title":"Postmortem Distribution of AB-CHMINACA, 5-fluoro-AMB, and Diphenidine in Body Fluids and Solid Tissues in a Fatal Poisoning Case: Usefulness of Adipose Tissue for Detection of the Drugs in Unchanged Forms","volume":"33","author":"Hasegawa","year":"2015","journal-title":"Forensic Toxicol."},{"key":"ref_57","first-page":"31","article-title":"Rapid and Sensitive Detection of Synthetic Cannabinoids AMB-FUBINACA and \u03b1-PVP Using Surface Enhanced Raman Scattering (SERS)","volume":"506","author":"Islam","year":"2018","journal-title":"J. Chem. Phys."},{"key":"ref_58","unstructured":"SNFL (2020, March 20). Analytical Report: FUB-AMB. Slovenija National Forensic Laboratory, Ljubljana, Available online: https:\/\/www.policija.si\/apps\/nfl_response_web\/0_Analytical_Reports_final\/AMB-FUBICA-ID-1657-16-rpt220916.pdf."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.forsciint.2017.09.017","article-title":"Assessment of Types of Synthetic Cannabinoids in Narcotic Cases Assessed by the Council of Forensic Medicine Between 2011\u20132015, Ankara, Turkey","volume":"280","year":"2017","journal-title":"Forensic Sci. Int."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/15563650.2017.1357826","article-title":"Synthetic Cannabinoid \u201cBlack Mamba\u201d Infidelity in Patients Presenting for Emergency Stabilization in Colorado: A P SCAN Cohort","volume":"56","author":"Brandehoff","year":"2018","journal-title":"Clin. Toxicol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jemermed.2018.09.012","article-title":"Coma, Seizures, Atrioventricular Block, and Hypoglycemia in an ADB-FUBINACA Body-packer","volume":"55","author":"Nacca","year":"2018","journal-title":"J. Emerg. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jflm.2019.04.012","article-title":"Fatal Intoxication of a Regular Drug user Following N-ethyl-hexedrone and ADB-FUBINACA Consumption","volume":"65","author":"Kereszty","year":"2019","journal-title":"J. Forensic Leg. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.forsciint.2018.11.003","article-title":"New Psychoactive Substances in Turkey: Narcotics Cases Assessed by the Council of Forensic Medicine Between 2016 and 2017 in Ankara, Turkey","volume":"294","year":"2019","journal-title":"Forensic Sci. Int."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"109960","DOI":"10.1016\/j.forsciint.2019.109960","article-title":"Identification of Synthetic Cannabinoids that Were Seized, Consumed, or Associated With Deaths in Kuwait in 2018 Using GC\u2013MS and LC\u2013MS-MS Analysis","volume":"303","author":"Alqallaf","year":"2019","journal-title":"Forensic Sci. Int."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/dta.2697","article-title":"Simultaneous Analysis of 29 Synthetic Cannabinoids and Metabolites, Amphetamines, and Cannabinoids in Human Whole Blood by Liquid Chromatography\u2013tandem Mass Spectrometry\u2013A New Zealand Perspective of Use in 2018","volume":"12","author":"Ong","year":"2020","journal-title":"Drug Test. Anal."},{"key":"ref_66","unstructured":"Lavado, E.L.J., Carapinha, L., Torrado, M., Frango, P., and Calado, V. (2018). New Psychoactive Substances in Portugal: Trendspotter Methodology\/Final Report, SICAD."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ajp.2016.10.019","article-title":"Ischemic Stroke Associated With the Use of a Synthetic Cannabinoid (Spice)","volume":"25","author":"Moeller","year":"2017","journal-title":"Asian J. Psychiatr."},{"key":"ref_68","unstructured":"EMCDDA (2017). European Drug Report 2017: Trends and Developments, European Union Publications Office. Available online: https:\/\/www.emcdda.europa.eu\/system\/files\/publications\/4541\/TDAT17001ENN.pdf."},{"key":"ref_69","unstructured":"EMCDDA (2019). European Drug Report 2019: Trends and Developments, European Union Publications Office. Available online: https:\/\/www.emcdda.europa.eu\/system\/files\/publications\/11364\/20191724_TDAT19001ENN_PDF.pdf."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cpem.2019.03.003","article-title":"Adolescents and Drug Abuse: 21st Century Synthetic Substances","volume":"20","author":"Yin","year":"2019","journal-title":"Clin. Pediatr. Emerg. Med."},{"key":"ref_71","unstructured":"DEA (2017). Schedules of Controlled Substances: Temporary Placement of Six Synthetic Cannabinoids (5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA) into Schedule I. Temporary Scheduling Order. Fed. Regist., 82, 17119\u201317124."},{"key":"ref_72","unstructured":"DEA (2020, March 30). Emerging Threat Report, Available online: https:\/\/ndews.umd.edu\/sites\/ndews.umd.edu\/files\/Emerging-Threat-Report-2018-Annual.pdf."},{"key":"ref_73","unstructured":"DEA (2020, March 30). Emerging Threat Report, Available online: https:\/\/ndews.umd.edu\/sites\/ndews.umd.edu\/files\/DEA-Emerging-Threat-Report-2019-Annual.pdf."},{"key":"ref_74","unstructured":"Decision, C. (2020, April 01). Proposal on the Position to Be Taken, on Behalf of the European Union, in the Sixty-second Session of the Commission on Narcotic Drugs on the Scheduling of Substances Under the Single Convention on Narcotic Drugs of 1961, as Amended. Available online: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=CELEX:52018PC0862."},{"key":"ref_75","unstructured":"DEA (2020, March 20). Placement of FUB-AMB in Schedule I, Available online: https:\/\/www.deadiversion.usdoj.gov\/fed_regs\/rules\/2020\/fr0330.htm."},{"key":"ref_76","unstructured":"DEA (2020, September 29). Placement of 5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA in Schedule I, Available online: https:\/\/www.deadiversion.usdoj.gov\/fed_regs\/rules\/2020\/fr0124.htm."},{"key":"ref_77","unstructured":"Government, C. (2020, March 15). Unauthorized Product Containing Synthetic Cannabinoids Sold from Stores in Edmonton. Recalls and Safety Alerts. Available online: http:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/hc-sc\/2017\/64304a-eng.php?_ga=2.231065567.1384206184.1517954225-1412185756.1513370286."},{"key":"ref_78","unstructured":"Services, A.H. (2020, March 15). AMB-FUBINACA & Other Synthetic Cannabinoids-Backgrounder. Alberta Addiction e Mental Health Research Partnership Program. Available online: https:\/\/www.albertahealthservices.ca\/assets\/info\/res\/mhr\/if-res-mhr-amb-fubinaca-backgrounder.pdf."},{"key":"ref_79","unstructured":"EMCDDA (2020, March 30). Regulation of the European Parliament and of the Council of 12 December 2006. Available online: https:\/\/eur-lex.europa.eu\/legal-content\/pt\/TXT\/?uri=CELEX%3A32006R1920."},{"key":"ref_80","unstructured":"BtMG (2020, March 20). Drug Trafficking Act (Narcotics Act-BtMG), Appendix II. German Controlled Substances Law. Available online: https:\/\/www.gesetze-im-internet.de\/btmg_1981\/anlage_ii.html."},{"key":"ref_81","unstructured":"Justice, M.O. (2020, March 21). Decree-Law n.\u00ba 15\/93 of 22 January. Available online: https:\/\/data.dre.pt\/eli\/dec-lei\/15\/1993\/01\/22\/p\/dre\/pt\/html."},{"key":"ref_82","unstructured":"Committee (2020, March 17). Craft n.\u00ba 71\/XIV\/1a-CACDLG\/2020. Assembly of the Republic Commission for Constitutional Affairs Rights Freedoms and Guarantees. Available online: http:\/\/app.parlamento.pt\/webutils\/docs\/doc.pdfpath6148523063446f764c324679626d56304c334e706447567a4c31684a566b786c5a793944543030764d554e425130524d5279394562324e31625756756447397a5357357059326c6864476c3259554e7662576c7a633246764c3249325a475a6d597a526a4c546b304d4749744e445a6959793035593251354c5745314d6d517a4d44686c5a4459354d4335775a47593d&fich=b6dffc4c-940b-46bc-9cd9-a52d308ed690.pdf&Inline=true&fbclid=IwAR3hGByRFkHzmsrauXgisEcHsHWfuxOqvODXriGrk8rp48W5z_lUTPcKBQE."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"93","DOI":"10.9740\/mhc.2019.03.093","article-title":"Review of the Many Faces of Synthetic Cannabinoid Toxicities","volume":"9","author":"Alipour","year":"2019","journal-title":"Ment. Health Clin."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3389\/fpubh.2018.00162","article-title":"Synthetic and Non-synthetic Cannabinoid Drugs and Their Adverse Effects-a Review from Public Health Prospective","volume":"6","author":"Cohen","year":"2018","journal-title":"Front. Public Health"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1360-0443.2012.04078.x","article-title":"Acute Toxicity Due to the Confirmed Consumption of Synthetic Cannabinoids: Clinical and Laboratory Findings","volume":"108","author":"Szabo","year":"2013","journal-title":"Addiction"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1080\/08897077.2016.1219438","article-title":"Acute Effects of Synthetic Cannabinoids: Update 2015","volume":"38","author":"Tournebize","year":"2016","journal-title":"Subst. Abus."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1021\/acschemneuro.9b00429","article-title":"Do Toxic Synthetic Cannabinoid Receptor Agonists Have Signature In Vitro Activity Profiles? A Case Study of AMB-FUBINACA","volume":"10","author":"Finlay","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"ref_88","unstructured":"Forum, D. (2020, March 20). FUB-AMB, AMB-FUBINACA. Available online: https:\/\/forum.dopalamy.com\/topic\/10829-fub-amb-amb-fubinaca\/?page=2."},{"key":"ref_89","unstructured":"Network, R.I. (2020, March 20). A Look so Far Into my Use of FUBAMB. Reddit Research Chemicals F\u00f3rum. Available online: https:\/\/www.reddit.com\/r\/researchchemicals\/comments\/4dre6j\/a_look_so_far_into_my_use_of_fubamb\/."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Davidson, C., Opacka-Juffry, J., Martin, A.A., Ovejero, D.G., Holgado, E.M., and Holgado, F.M. (2017). Spicing Up Pharmacology: A Review of Synthetic Cannabinoids from Structure to Adverse Events. Adv. Pharm., 135\u2013168.","DOI":"10.1016\/bs.apha.2017.05.001"},{"key":"ref_91","first-page":"650","article-title":"Rhabdomyolysis Associated With Laboratory Confirmed FUB-AMB Use","volume":"53","author":"Thornton","year":"2015","journal-title":"Clin. Toxicol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"109892","DOI":"10.1016\/j.forsciint.2019.109892","article-title":"Fatalities Related to New Psychoactive Substances in Singapore\u2014A Case Series","volume":"304","author":"Chan","year":"2019","journal-title":"Forensic Sci. Int."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1212\/WNL.0000000000001973","article-title":"Hemorrhagic Stroke Following Use of the Synthetic Marijuana \u201cSpice\u201d","volume":"85","author":"Rose","year":"2015","journal-title":"Neurology"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1212\/01.wnl.0000437297.05570.a2","article-title":"Ischemic Stroke After Use of the Synthetic Marijuana \u201cSpice\u201d","volume":"81","author":"Freeman","year":"2013","journal-title":"Neurology"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.brainresbull.2015.10.013","article-title":"The Behavioral Profile of Spice and Synthetic Cannabinoids in Humans","volume":"126","author":"Kornhuber","year":"2016","journal-title":"Brain Res. Bull."},{"key":"ref_96","unstructured":"Bracewell-Worrall, A. (2020, March 16). Synthetic Drugs Kill 45 People in One Year\u2014Coroner. Available online: https:\/\/www.newshub.co.nz\/home\/politics\/2018\/07\/synthetic-drugs-kills-45-people-in-one-year-coroner.html."},{"key":"ref_97","unstructured":"Kappatos, D.J.C., and Ong, R. (2018, January 26\u201330). \u2018Border to Grave\u2019 Surveillance of New Psychoactive Substances in New Zealand: The Dramatic Impact of AMB-FUBINACA. Proceedings of the Flash presentation at 56th TIAFT Annual Meeting, Ghent, Belgium."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neuro.2018.11.004","article-title":"Cannabinoid-like Effects of Five Novel Carboxamide Synthetic Cannabinoids","volume":"70","author":"Gatch","year":"2019","journal-title":"Neurotoxicology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.forsciint.2014.11.012","article-title":"Concentrations of APINACA, 5F-APINACA, UR-144 and Its Degradant Product in Blood Samples from Six Impaired Drivers Compared to Previous Reported Concentrations of Other Synthetic Cannabinoids","volume":"246","author":"Karinen","year":"2015","journal-title":"Forensic Sci. Int."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2131\/jts.42.335","article-title":"Pyrolysis of UR-144, a Synthetic Cannabinoid, Augments an Affinity to Human CB1 Receptor and Cannabimimetic Effects in Mice","volume":"42","author":"Funada","year":"2017","journal-title":"J. Toxicol. Sci."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1124\/jpet.116.238717","article-title":"Thermolytic Degradation of Synthetic Cannabinoids: Chemical Exposures and Pharmacological Consequences","volume":"361","author":"Thomas","year":"2017","journal-title":"J. Pharm. Exp."},{"key":"ref_102","first-page":"317","article-title":"Epoxides\u2014Is there a Human Health Problem?","volume":"37","author":"Manson","year":"1980","journal-title":"Br. J. Ind. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1021\/acscentsci.5b00131","article-title":"Modeling Epoxidation of Drug-like Molecules with a Deep Machine Learning Network","volume":"1","author":"Hughes","year":"2015","journal-title":"ACS Cent. Sci."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"8885","DOI":"10.1016\/S0040-4020(01)85362-X","article-title":"Chemical and Biological Synthesis of Chiral Epoxides","volume":"50","author":"Besse","year":"1994","journal-title":"Tetrahedron"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11920-016-0694-1","article-title":"Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal","volume":"18","author":"Cooper","year":"2016","journal-title":"Curr. Psychiatry Rep."},{"key":"ref_106","first-page":"310930","article-title":"Synthetic Cannabis-induced Mania","volume":"2015","author":"Ustundag","year":"2015","journal-title":"Case Rep. Psychiatry"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/dta.2607","article-title":"Functional Evaluation of Carboxy Metabolites of Synthetic Cannabinoid Receptor Agonists Featuring Scaffolds Based on l-valine or l-tert-leucine","volume":"11","author":"Wouters","year":"2019","journal-title":"Drug Test. Anal."},{"key":"ref_108","first-page":"294","article-title":"Cannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease","volume":"10","author":"Kendall","year":"2016","journal-title":"Front. Cell. Neurosci."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1124\/mol.116.104539","article-title":"The Multiple Waves of Cannabinoid 1 Receptor Signaling","volume":"90","author":"Yudowski","year":"2016","journal-title":"Mol. Pharm."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Zou, S., and Kumar, U. (2018). Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19030833"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s11419-016-0316-y","article-title":"The 2-alkyl-2H-indazole Regioisomers of Synthetic Cannabinoids AB-CHMINACA, AB-FUBINACA, AB-PINACA, and 5F-AB-PINACA are Possible Manufacturing Impurities With Cannabimimetic Activities","volume":"34","author":"Longworth","year":"2016","journal-title":"Forensic Toxicol."},{"key":"ref_112","first-page":"1178221817701739","article-title":"Vaping Synthetic Cannabinoids: A Novel Preclinical Model of E-cigarette Use in Mice","volume":"11","author":"Lefever","year":"2017","journal-title":"Subst. Abus."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"11476","DOI":"10.1021\/acs.analchem.6b02600","article-title":"Detection and Activity Profiling of Synthetic Cannabinoids and Their Metabolites With a Newly Developed Bioassay","volume":"88","author":"Cannaert","year":"2016","journal-title":"Anal. Chem."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00216-015-9116-1","article-title":"Determination of Urinary Metabolites of XLR-11 by Liquid Chromatography\u2013quadrupole Time-of-flight Mass Spectrometry","volume":"408","author":"Jang","year":"2016","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/dta.1896","article-title":"Identification of AB-FUBINACA Metabolites in Authentic Urine Samples Suitable as Urinary Markers of Drug Intake Using Liquid Chromatography Quadrupole Tandem Time of Flight Mass Spectrometry","volume":"8","author":"Vikingsson","year":"2016","journal-title":"Drug Test. Anal."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11419-017-0361-1","article-title":"In Vitro and In Vivo Pharmacokinetics and Metabolism of Synthetic Cannabinoids CUMYL-PICA and 5F-CUMYL-PICA","volume":"35","author":"Kevin","year":"2017","journal-title":"Forensic Toxicol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.ajem.2018.12.044","article-title":"Suspected Synthetic Cannabinoid Receptor Agonist Intoxication: Does Analysis of Samples Reflect the Presence of Suspected Agents?","volume":"37","author":"Tebo","year":"2019","journal-title":"Am. J. Emerg. Med."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/14\/3\/186\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:28:47Z","timestamp":1760160527000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/14\/3\/186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,25]]},"references-count":117,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["ph14030186"],"URL":"https:\/\/doi.org\/10.3390\/ph14030186","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,25]]}}}